Editorial Standards

Our Editorial Mission

Alpine Research Labs is committed to being the definitive reference for peptide research information. We aim to present complex biochemical research in an accurate, accessible format that serves researchers, students, and the scientific community. Our content is written to inform and educate—never to promote or make therapeutic claims.

Content Creation Process

1. Research and Drafting

All research content—monographs, guides, and study summaries—is drafted by the Alpine Labs Editorial Team. Our editorial team draws on expertise in biochemistry, pharmacology, neuroscience, endocrinology, and analytical chemistry.

Authors draw exclusively from peer-reviewed primary literature, with preference given to studies published in indexed journals with established impact factors. We do not cite press releases, pre-prints without peer review, manufacturer claims, or anecdotal reports as primary evidence.

2. Scientific Review

Every monograph and research guide undergoes independent scientific review before publication. Our review process evaluates each piece for:

• Scientific accuracy — Are claims supported by the cited evidence? Are findings from animal studies clearly distinguished from human clinical data?
• Citation integrity — Do citations accurately represent their source material? Are DOI links valid and correctly attributed?
• Methodological context — Are study limitations, sample sizes, and research phases clearly communicated?
• Language precision — Is speculative language used appropriately? Do we avoid definitive claims where evidence is preliminary?
• Completeness — Does the content cover the current state of research without significant omissions?

3. Publication and Updates

Published content displays both the original publication date and the most recent update date. We review content on a quarterly basis and update articles when:

• Significant new research is published that changes the scientific understanding
• Corrections are needed based on reader feedback or internal review
• Clinical trial status changes (e.g., new phases begun or completed)
• Regulatory developments affect the research landscape

Citation Standards

We maintain strict citation standards across all research content:

• Primary sources only — We cite original peer-reviewed research papers, not secondary summaries or derivative content
• DOI linking — Every citation includes a Digital Object Identifier (DOI) link where available, providing permanent access to the source material
• Author attribution — Full author lists (or et al. for groups larger than 4) with journal name and publication year
• Inline citation — Key claims are cited at the point of reference, not just in an end-of-article bibliography
• Recency preference — We prioritize recent research (last 10 years) while including foundational studies where relevant

Editorial Team

All research content is produced by the Alpine Labs Editorial Team. Our editorial team spans expertise in peptide biochemistry, molecular pharmacology, endocrinology, neuroscience, and analytical chemistry.

Learn more about our editorial process.

Scientific Review Process

Our scientific review process is independent from content creation. The review editor does not author content, ensuring an unbiased evaluation. The review process includes:

1. Fact verification — Every factual claim is traced back to its cited source and verified
2. Source validation — Referenced studies are confirmed to exist in PubMed or the stated journal database
3. Bias assessment — Content is evaluated for unintentional bias toward positive findings or commercial implications
4. Readability review — Scientific accuracy is balanced with accessibility for a technical but non-specialist audience

Articles that pass review display a "Reviewed by Alpine Labs Editorial Team" attribution in the article header. Articles under review or awaiting update are clearly marked.

Conflict of Interest Disclosure

Alpine Research Labs is a commercial entity that sells research-grade peptides. We recognize this creates an inherent potential conflict of interest when publishing research content about the compounds we sell. We address this through the following measures:

• Transparent relationship — Every monograph that references a product available in our catalog includes an explicit disclosure noting the commercial relationship
• No exaggerated claims — Our editorial policy prohibits language that overstates research findings or implies therapeutic efficacy. We use hedging language ("research suggests," "studies indicate") consistently
• Negative findings included — We report study limitations, negative results, and discontinued research alongside positive findings
• Independent review — The review editor evaluates content specifically for commercial bias
• No financial incentives for authors — Research team compensation is not tied to product sales or content performance metrics

Correction Policy

We are committed to accuracy and will promptly correct errors when identified:

• Minor corrections (typos, formatting, broken links) are fixed immediately and the update date is revised
• Substantive corrections (factual errors, misrepresented findings, incorrect citations) include a correction note at the top of the article explaining what was changed and why
• Retractions — If a cited study is retracted, we update the relevant content within 30 days, noting the retraction and adjusting conclusions as needed

To report an error or suggest a correction, contact our research team at research@alpineresearchlabs.com.

Content Scope and Limitations

Our research content covers peptides and related compounds that are subjects of active scientific investigation. We explicitly acknowledge these limitations:

• The majority of peptide research is preclinical (animal models and in vitro studies). We clearly label the research phase for all findings discussed.
• Our content is not medical advice and should not be used to make healthcare decisions.
• Products sold on this site are intended for laboratory and research use only.
• We do not cover off-label human use, self-experimentation protocols, or dosing for human consumption.